Divergence of gut permeability and mucosal immune gene expression in two gluten-associated conditions: celiac disease and gluten sensitivity
Top Cited Papers
Open Access
- 9 March 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Medicine
- Vol. 9 (1), 23
- https://doi.org/10.1186/1741-7015-9-23
Abstract
Celiac disease (CD) is an autoimmune enteropathy triggered by the ingestion of gluten. Gluten-sensitive individuals (GS) cannot tolerate gluten and may develop gastrointestinal symptoms similar to those in CD, but the overall clinical picture is generally less severe and is not accompanied by the concurrence of tissue transglutaminase autoantibodies or autoimmune comorbidities. By studying and comparing mucosal expression of genes associated with intestinal barrier function, as well as innate and adaptive immunity in CD compared with GS, we sought to better understand the similarities and differences between these two gluten-associated disorders. CD, GS and healthy, gluten-tolerant individuals were enrolled in this study. Intestinal permeability was evaluated using a lactulose and mannitol probe, and mucosal biopsy specimens were collected to study the expression of genes involved in barrier function and immunity. Unlike CD, GS is not associated with increased intestinal permeability. In fact, this was significantly reduced in GS compared with controls (P = 0.0308), paralleled by significantly increased expression of claudin (CLDN) 4 (P = 0.0286). Relative to controls, adaptive immunity markers interleukin (IL)-6 (P = 0.0124) and IL-21 (P = 0.0572) were expressed at higher levels in CD but not in GS, while expression of the innate immunity marker Toll-like receptor (TLR) 2 was increased in GS but not in CD (P = 0.0295). Finally, expression of the T-regulatory cell marker FOXP3 was significantly reduced in GS relative to controls (P = 0.0325) and CD patients (P = 0.0293). This study shows that the two gluten-associated disorders, CD and GS, are different clinical entities, and it contributes to the characterization of GS as a condition associated with prevalent gluten-induced activation of innate, rather than adaptive, immune responses in the absence of detectable changes in mucosal barrier function.This publication has 47 references indexed in Scilit:
- Alterations of the Intestinal Barrier in Patients With Autism Spectrum Disorders and in Their First‐degree RelativesJournal of Pediatric Gastroenterology and Nutrition, 2010
- Differential Mucosal IL-17 Expression in Two Gliadin-Induced Disorders: Gluten Sensitivity and the Autoimmune Enteropathy Celiac DiseaseInternational Archives of Allergy and Immunology, 2009
- Prevalence of Celiac Disease and Gluten Sensitivity in the United States Clinical Antipsychotic Trials of Intervention Effectiveness Study PopulationSchizophrenia Bulletin, 2009
- Between Celiac Disease and Irritable Bowel Syndrome: The “No Man's Land” of Gluten SensitivityThe American Journal of Gastroenterology, 2009
- Interleukin-23 and Th17 Cells in the Control of Gut InflammationMediators of Inflammation, 2009
- Celiac diseaseCurrent Opinion in Gastroenterology, 2008
- Toward the Assessment of Food Toxicity for Celiac Patients: Characterization of Monoclonal Antibodies to a Main Immunogenic Gluten PeptidePLOS ONE, 2008
- Alterations in intestinal permeabilityGut, 2006
- In Celiac Disease, a Subset of Autoantibodies against Transglutaminase Binds Toll-Like Receptor 4 and Induces Activation of MonocytesPLoS Medicine, 2006
- IL-23 is essential for T cell–mediated colitis and promotes inflammation via IL-17 and IL-6JCI Insight, 2006